Body weight cycling, also known as “yo-yo dieting,” is associated with a 25%-36% increased risk for diabetic kidney disease ...

“According to Anderson Moores veterinary specialists, there were 18 cases of Alabama rot reported in 2024, which is thankfully a very small proportion of the 10.6 million pet dogs in the UK, although ...

Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in people with type 1 diabetes, regardless of body mass index (BMI) and other ...

Among Black patients with suppressed HIV, estimated glomerular filtration rate by cystatin C appears to provide clinically useful information regardless of ART regimen.

Scientist develop new equation for detecting hyperfiltration that incorporates age but not body surface area. Read more!

H.C. Wainwright lowered the firm’s price target on PepGen (PEPG) to $16 from $26 and keeps a Buy rating on the shares after the company shared the safety reports from the CONNECT1-EDO51, the Phase 2, ...

Zevra to receive a 2025 New Treatment Award for MIPLYFFA™ at the 21st Annual WORLDSymposiumEight abstracts discussing data and clinical ...

PepGen (PEPG) “provided recent updates on its CONNECT clinical program investigating PGN-EDO51 in Duchenne muscular dystrophy for patients ...

The following is a summary of “Prognostic impact of albuminuria in early-stage chronic kidney disease on cardiovascular outcomes: a cohort study,” published in the January 2025 issue of Cardiology by ...

Statins, a class of cholesterol-lowering drugs, have no effect on kidney function, a research team led by the University of Iowa has found.

No randomized clinical trials have directly compared empagliflozin with dapagliflozin for type 2 diabetes, so investigators conducted a large comparative effectiveness study examining kidney outcomes.

A University of Iowa research team has found that a class of cholesterol-lowering drugs have no effect on kidney function.